Hutchison China MediTech Limited Overview
HUTCHMED is a Hong Kong-headquartered, China-rooted, commercial-stage biopharmaceutical company. It discovers small-molecule targeted therapies in-house and commercializes them in China through its own oncology salesforce. Outside China it monetizes them through licensing with multinational partners: Takeda (FRUZAQLA), AstraZeneca (ORPATHYS) and, since September 2026, GSK (HMPL-A830). Its anchor asset, fruquintinib, posted $366.2 million of global in-market sales outside China in FY2025, and approvals or launches now span 41 countries. The company has been profitable for three consecutive years (FY2023 to FY2025). After selling its 45% stake in the Shanghai Hutchison Pharmaceuticals joint venture, it held $1.37 billion of cash and short-term investments (June 2026). Its strategic pivot is toward Antibody-Targeted Therapy Conjugates (ATTCs). These conjugate its proprietary kinase-inhibitor payloads to antibodies, and three candidates had entered clinical trials by September 2026. Its main differentiator is kinase selectivity. Its main vulnerabilities are China pricing and reimbursement pressure, concentration in a few assets, and an extended CEO leave of absence.
Company's own description (paraphrased from the FY2025 and 2026 announcements). HUTCHMED describes itself as an innovative, commercial-stage biopharmaceutical company. It aims to discover targeted therapies and immunotherapies for cancer and immunological diseases and to develop and commercialize them globally. It emphasizes that since inception it has taken drug candidates from in-house discovery to patients worldwide. Four medicines are now marketed in China (fruquintinib, surufatinib, savolitinib and fanregratinib, the last approved in August 2026). The first of these, fruquintinib, is approved in the US, Europe and Japan.
Business model and revenue model. HUTCHMED reports two segments: Oncology/Immunology and Other Ventures. Oncology/Immunology revenue has five components:
-
Direct product sales in China. SULANDA is sold by HUTCHMED itself. TAZVERIK was also sold this way until its withdrawal in 2026.
-
Manufacturing revenue. HUTCHMED supplies drug product to partners: Takeda for FRUZAQLA, Eli Lilly for ELUNATE, and AstraZeneca for ORPATHYS.
-
Royalties on partner in-market sales.
-
Promotion and marketing services revenue. For example, fees paid by Lilly for ELUNATE in China.
-
Upfront, milestone, licensing and R&D-services revenue. This includes Takeda's upfront and milestones, AstraZeneca milestones, the Lilly milestone triggered by the 2L RCC approval, and, from closing, the GSK upfront.
Other Ventures is mostly a low-margin prescription drug distribution business in China. Until April 2025 it also included equity-method earnings from the SHPL joint venture; HUTCHMED now holds only 5% of SHPL.
Revenue mix, FY2025 (company-reported).
Value chain position. HUTCHMED is vertically integrated in China, covering discovery, clinical development, regulatory work, manufacturing and commercial sales. Outside China it is an originator and licensor: it supplies drug product and receives royalties, while partners run global late-stage development and commercialization.
Customers and end markets.
-
In China: hospital oncology departments, distributors, and the National Reimbursement Drug List (NRDL) payer system.
-
Outside China: pharmaceutical partners (Takeda, AstraZeneca, Lilly, GSK).
Therapeutic end markets are colorectal cancer, neuroendocrine tumors, non-small cell lung cancer (NSCLC), gastric cancer, endometrial cancer, renal cell carcinoma, intrahepatic cholangiocarcinoma, follicular lymphoma, and two immune hematology conditions: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA).
Independent characterization. HUTCHMED is best understood as a hybrid. Its China business is a mid-sized specialty oncology franchise. Its global business is a royalty and licensing engine. Behind both sits a discovery platform that has repeatedly produced highly selective kinase inhibitors.
Consolidated revenue overstates the economic weight of the distribution business. Other Ventures was 48% of FY2025 revenue but contributed only $25.5 million of net income. Conversely, consolidated revenue understates the reach of the drugs, because in-market sales of $524.7 million in FY2025 were about 2.4x consolidated oncology product revenue.
The investment case now rests on three things:
-
continued FRUZAQLA royalty growth;
-
recovery of China product sales, which rose 32% in H1 2026;
-
the ATTC platform, now externally validated by the GSK deal.
Strategy
Stated strategic themes (paraphrased from the FY2025 and 2026 interim results):
-
A globally competitive oncology portfolio anchored by differentiated innovation. The chairman, in July 2026, described ATTC payload platforms and other emerging large-molecule modalities as the future core, aiming for first-in-class or best-in-class assets.
-
Partner-led globalization. The FRUZAQLA–Takeda template is being applied to ATTCs. The first instance was the HMPL-A830 license to GSK in September 2026, and management says further multinational partnerships are under discussion.
-
A self-funding, profitable China commercial engine. The 2025 salesforce restructuring, compliance upgrade and focus on top-tier hospitals delivered over 40% growth for both ELUNATE and SULANDA in H1 2026.
-
Discovery strengthened through talent and AI capabilities. Management cited AI tools in drug creation.
-
Capital deployment. The company plans to use $1.4 billion of cash to accelerate ATTC global development and to explore in-licensing, M&A and investment opportunities.
-
Pruning non-core assets. This produced the SHPL divestment in 2025.
Guidance.
-
FY2026 Oncology/Immunology consolidated revenue of $330–450 million, set on 5 March 2026 and reiterated on 30 July 2026. H1 2026 delivered $162.3 million.
-
No medium-term margin or EPS targets are published.
-
Management's stated aim is to remain financially self-sufficient while increasing R&D investment.
Products & Services
Marketed products (Oncology/Immunology)
FRUZAQLA / ELUNATE (fruquintinib)
Mechanism: highly selective oral VEGFR-1, -2 and -3 inhibitor.
Brands and partners: sold as ELUNATE in China (partnered with Eli Lilly) and as FRUZAQLA outside China (licensed to Takeda since January 2023).
Approved indications: - 3L+ metastatic colorectal cancer (mCRC) in China, the US, EU, Japan and others;
-
2L endometrial cancer with pMMR, combined with sintilimab, in China (NRDL coverage expanded in 2026);
-
2L renal cell carcinoma (RCC), combined with sintilimab, in China, approved May 2026.
Commercial reach: FRUZAQLA is approved or launched in 41 countries (as of July 2026) and reimbursed in almost 20 (as of March 2026), with recent reimbursement in France (Q1 2026) and a UK NICE recommendation.
Key data: the FRUSICA-2 trial in 2L RCC showed median progression-free survival (PFS) of 22.2 vs 6.9 months against axitinib or everolimus (HR 0.373) and an objective response rate (ORR) of 60.5% vs 24.3%.
Sales: - FY2025: FRUZAQLA in-market $366.2 million (+26%); consolidated revenue $89.4 million.
-
FY2025: ELUNATE in-market $100.1 million (−13%); consolidated revenue $76.9 million.
-
H1 2026: FRUZAQLA in-market $185.4 million; ELUNATE in-market $60.8 million (+41%).
Pricing model: royalties plus manufacturing revenue from Takeda; manufacturing, promotion and marketing fees plus royalties from Lilly. Price levels not publicly disclosed.
SULANDA (surufatinib)
Mechanism: oral inhibitor of VEGFR, FGFR1 and CSF-1R.
Approved indications: pancreatic and non-pancreatic neuroendocrine tumors (NETs) in China. Fully owned and commercialized by HUTCHMED.
Positioning: in 2026 the Chinese Society of Clinical Oncology (CSCO) guidelines upgraded its NET recommendation to the highest Level I. The NRDL listing was renewed without a price cut (FY2025 results webcast).
Sales: FY2025 $27.0 million (−45%, hit by new NRDL competitors); H1 2026 $18.4 million (+45%).
Pipeline: a Phase III trial began in December 2025 in 1L metastatic pancreatic cancer (PDAC), combined with camrelizumab, nab-paclitaxel and gemcitabine. The Phase II portion showed median PFS of 7.2 vs 5.5 months (HR 0.499).
ORPATHYS (savolitinib)
Mechanism: oral, highly selective MET tyrosine kinase inhibitor. Co-developed with AstraZeneca, which commercializes it.
Approved indications in China: - METex14 NSCLC: full approval in 1L and 2L (January 2025);
-
with TAGRISSO, 2L EGFRm NSCLC with MET amplification after an EGFR-TKI (SACHI trial; June 2025);
-
3L MET-amplified gastric cancer (June 2026).
Other approvals: Hong Kong (February 2025) and a Swiss temporary authorization with TAGRISSO (February 2026).
US filing: NDA submitted by AstraZeneca on 28 September 2026, supported by SAFFRON.
Sales: FY2025 in-market $28.9 million, consolidated revenue $18.6 million; H1 2026 in-market $15.7 million, consolidated revenue $13.3 million.
Key data: - SACHI: median PFS of 8.2 vs 4.5 months (HR 0.34) in the overall population; subgroup median overall survival (OS) of 22.9 vs 7.9 months (The Lancet, January 2026).
-
Gastric cancer Phase II: ORR 32.3%.
-
SAFFRON (338 patients, 29 countries): statistically significant PFS and OS benefit.
-
SANOVO (326 patients, 1L, China): statistically significant PFS benefit in both high-MET and overall populations.
ATLED (fanregratinib, HMPL-453)
Mechanism: selective FGFR1, FGFR2 and FGFR3 inhibitor.
Approval: NMPA approved on 27 August 2026 for 2L FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma (ICC).
Key data: pivotal Phase II ORR 42.5%, median PFS 6.9 months, median OS 16.6 months.
Status: wholly owned; launch status and price not publicly disclosed.
TAZVERIK (tazemetostat)
Mechanism: EZH2 inhibitor. Ipsen holds the marketing authorization; HUTCHMED acted as China agent and licensee.
History: conditionally approved in China in March 2025 for 3L EZH2-mutant follicular lymphoma; voluntarily withdrawn by Ipsen in March 2026 after safety signals in the SYMPHONY-1 trial.
Sales: FY2025 revenue $2.5 million; H1 2026 −$0.5 million (returns).
ATTC platform: Antibody-Targeted Therapy Conjugates
An ATTC links a proprietary small-molecule kinase-inhibitor payload to a monoclonal antibody through a cleavable linker. Unlike conventional antibody-drug conjugates, which carry cytotoxic payloads, ATTCs carry targeted-therapy payloads. The aim is a dual mechanism with less off-tumor toxicity.
Out-licensed and partnered discovery assets
IMG-007: (non-T-cell-depleting OX40 antagonist), developed by ImageneBio; HUTCHMED owns about 3.8%. A Phase IIb trial in atopic dermatitis is running, with topline data expected in Q4 2027. A Phase II in alopecia areata is planned for 2026.
Other Ventures
- Residual 5% stake in SHPL, which makes own-brand cardiovascular prescription medicines. HUTCHMED guaranteed a minimum net profit growth of about 5% a year for three years, with compensation capped at about $95 million.
Product Portfolio
| Asset | Target | Status (October 2026) | Rights |
|---|---|---|---|
Sovleplenib (HMPL-523) | Syk | China NDAs accepted with priority review: 2L ITP (resubmitted February 2026) and 2L wAIHA (April 2026). ESLIM-02 durable response rate 66.0% | HUTCHMED; seeking an ex-China partner |
HMPL-760 | Third-generation non-covalent BTK | China Phase III with R-GemOx in 2L DLBCL, started March 2026 | HUTCHMED |
Savolitinib, 1L NSCLC | MET | SANOVO positive (August 2026); China filing expected | AstraZeneca / HUTCHMED |
Surufatinib, 1L PDAC | VEGFR/FGFR1/CSF-1R | Phase III part began December 2025 | HUTCHMED |
| Candidate | Payload / Antibody target | Status | Rights |
|---|---|---|---|
HMPL-A251 | PI3K/PIKK / HER2 | Global Phase I/IIa; first patient dosed December 2025 | HUTCHMED |
HMPL-A580 | PI3K/PIKK / EGFR | Global trial; first patient dosed March 2026 | HUTCHMED |
HMPL-A830 | KRAS / EGFR | China and US INDs cleared July 2026; global trial started 27 September 2026 | GSK outside Greater China; HUTCHMED in Greater China |
Earlier ATTCs | — | Preclinical; GSK holds a right of first negotiation on one | HUTCHMED |
“—” = not publicly disclosed.
Financial Narrative
Sources: S&P Global Market Intelligence and Fiscal.ai standardized data via StockAnalysis.com for FY2021 to FY2025. FY2024 and FY2025 were cross-checked against the company's FY2025 results announcement, and company figures are used where they differ. All figures in USD M unless stated.
Income statement
Margins:
Revenue CAGR, FY2021 to FY2025: about 11.4% a year. It is distorted by the FY2023 peak, when the Takeda upfront was recognized.
Commentary.
Revenue: The five-year arc has three phases:
-
FY2021–FY2022: heavy losses during a global build-out, with R&D peaking at $386.9 million in FY2022.
-
FY2023: an inflection driven by the Takeda transaction. Oncology/Immunology R&D revenue reached $364.5 million.
-
FY2024–FY2025: normalization. Licensing revenue tapered and China sales hit headwinds.
The FY2025 revenue decline of 13% has three causes, per company disclosures:
-
the absence of a $20 million Takeda commercial milestone that was booked in FY2024;
-
lower Takeda R&D services revenue ($51.6 million vs $67.0 million);
-
China sales headwinds in H1 2025, from compliance-driven commercial changes, salesforce streamlining and new NRDL competitors for SULANDA.
Profitability: Gross margin compressed from 54% in FY2023 to 39% in FY2025 as high-margin licensing revenue fell as a share of the total. Cost of revenue as a share of oncology product revenue rose to 39% in FY2025 from 34% in FY2024, then improved to 33% in H1 2026.
Cost discipline: R&D more than halved from its FY2022 peak to $148.3 million in FY2025 as costly late-stage trials finished. China R&D fell by $36.2 million and US R&D by $27.6 million. Selling and administrative costs fell to $103.0 million.
Operating vs net result: The group remained marginally loss-making at the operating line. It was profitable below the line because of interest income of $49.9 million in FY2025 on a large cash pile, plus SHPL equity earnings. FY2025 net income of $456.9 million is dominated by the SHPL gain: $476.9 million pre-tax, or $415.8 million net of tax. Stripping out the gain, underlying net income was about $41 million.
H1 2026: Revenue was $278.3 million, R&D rose to $78.8 million, and net income was $15.9 million.
Balance sheet (year-end)
At 30 June 2026: cash and short-term investments were $1,374.8 million, bank borrowings $94.5 million, total equity (company shareholders) $1,260.8 million, and deferred revenue $27.6 million, down from $51.5 million at end-2025.
Commentary. The balance sheet is very liquid. Net cash of about $1.28 billion is roughly half the market capitalization (June 2026). Debt is small and consists of local bank facilities. Deferred revenue is unwinding as Takeda-related obligations are fulfilled. The GSK upfront of $110 million, receivable on closing subject to antitrust clearance, will add to cash in H2 2026 if the deal closes. Goodwill and intangibles are negligible, so equity is almost entirely tangible.
Cash flow
Notes:
-
FY2025 operating cash flow was depressed partly by the $59.5 million capital gains tax on the SHPL sale, while the $608.5 million gross proceeds are classified as investing. The company's non-GAAP adjusted net cash inflow excluding financing was $523.3 million.
-
FY2024 financing included $36.1 million of share purchases for equity awards through a trust. These are not cancellation buybacks.
-
H1 2026: adjusted non-GAAP net cash inflow of $10.5 million; capex $5.6 million.
Ratios (derived from the tables above)
Notes:
ROIC: not meaningful. Invested capital net of cash is negative; S&P computes −1,741.75% on a trailing basis.
Net debt to EBITDA: not meaningful; the company is in a net cash position.
Interest coverage (EBIT ÷ interest expense): 24x in FY2023; negative in all other years.
Cash conversion cycle: not publicly disclosed in usable form. Inventory turnover is 10.7x on a trailing basis (S&P).
Trend summary. Returns ratios are dominated by one-off items: the Takeda upfront in FY2023 and the SHPL gain in FY2025. Underlying ROE excluding the SHPL gain was about 4% in FY2025. Leverage is negligible. The key financial question is no longer solvency. It is whether recurring product and royalty income can fund a rising ATTC R&D budget while keeping the company self-funding, which management has stated is its aim.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (USD Mn)
| Segment revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Oncology/Immunology Marketed Products | 164.2 | 271.5 | 214.4 |
Oncology/Immunology R&D | 364.5 | 91.8 | 71.2 |
Oncology/Immunology total | 528.6 | 363.4 | 285.5 |
Other Ventures | 309.4 | 266.8 | 263.0 |
Total revenue | 838.0 | 630.2 | 548.5 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Oncology/Immunology share of revenue | 63.1 | 57.7 | 52.1 |
Other Ventures share of revenue | 36.9 | 42.3 | 47.9 |
Oncology/Immunology YoY growth | 222.6 | -31.3 | -21.4 |
Other Ventures YoY growth | 17.8 | -13.8 | -1.4 |
Other Ventures net income attributable (USD Mn)
| Other Ventures net income attributable (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Net income from Other Ventures | 47.7 | 25.5 |
Business Lines
| Line | H1 2025 | H1 2026 | Change % |
|---|---|---|---|
Oncology products | 99.1 | 121.4 | 23 |
Takeda upfront, milestones and R&D services | 29.5 | 20.7 | -30 |
Other R&D services and licensing | 14.9 | 20.2 | 35 |
Oncology/Immunology total | 143.5 | 162.3 | 13 |
Other Ventures | 134.2 | 116.0 | -14 |
Total | 277.7 | 278.3 | 0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (USD Mn) | 356.1 | 426.4 | 838.0 | 630.2 | 548.5 |
Revenue growth (%) | 56.2 | 19.7 | 96.5 | -24.8 | -13.0 |
Cost of revenue (USD Mn) | 258.2 | 311.1 | 384.5 | 348.9 | 336.3 |
Gross profit (USD Mn) | 97.9 | 115.3 | 453.6 | 281.3 | 212.2 |
R&D expense (USD Mn) | 299.1 | 386.9 | 302.0 | 212.1 | 148.3 |
Selling and administrative (USD Mn) | 127.1 | 136.1 | 133.2 | 112.9 | 103.0 |
Operating income (USD Mn) | -328.3 | -407.7 | 18.4 | -43.7 | -39.2 |
EBITDA (USD Mn) | -321.1 | -399.0 | 26.6 | -31.4 | -25.9 |
Pre-tax income (USD Mn) | -155.1 | -360.7 | 105.6 | 45.4 | 521.3 |
Net income attributable (USD Mn) | -194.7 | -360.8 | 100.8 | 37.7 | 456.9 |
EPS basic per ordinary share (USD) | -0.25 | -0.43 | 0.12 | 0.04 | 0.53 |
EPS diluted per ordinary share (USD) | -0.25 | -0.43 | 0.12 | 0.04 | 0.52 |
EPS basic per ADS (USD) | -1.25 | -2.15 | 0.60 | 0.22 | 2.66 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 27.5 | 27.0 | 54.1 | 44.6 | 38.7 |
Operating margin | -92.2 | -95.6 | 2.2 | -6.9 | -7.1 |
EBITDA margin | -90.2 | -93.6 | 3.2 | -5.0 | -4.7 |
Net margin (attributable) | -54.7 | -84.6 | 12.0 | 6.0 | 83.3 |
Balance Sheet
| Metric (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 1,373.0 | 1,029.0 | 1,280.0 | 1,274.2 | 1,753.1 |
Cash, equivalents and short-term investments | 1,014.0 | 633.3 | 889.0 | 836.1 | 1,367.3 |
Short-term debt (current portion) | 26.9 | 0.0 | 31.2 | 23.4 | 25.0 |
Long-term debt | 0.0 | 18.1 | 48.2 | 59.4 | 68.2 |
Total debt incl. leases | 39.0 | 27.0 | 86.1 | 89.8 | 97.9 |
Net debt (negative = net cash) | -975.5 | -606.3 | -802.9 | -748.2 | -1,271.0 |
Total equity incl. minorities | 1,040.0 | 636.9 | 743.4 | 771.9 | 1,251.3 |
Shareholders' equity (company) | 986.9 | 610.4 | 730.5 | 759.9 | 1,237.9 |
Goodwill | 0.0 | 0.0 | 0.0 | 3.0 | 3.1 |
Working capital | 900.4 | 486.0 | 693.8 | 690.0 | 1,252.0 |
Cash Flow
| Metric (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | -204.2 | -268.6 | 219.3 | 0.5 | -64.7 |
Capital expenditure | -16.4 | -36.7 | -32.6 | -17.9 | -14.2 |
Free cash flow | -220.6 | -305.3 | 186.7 | -17.4 | -78.8 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on average company equity (%) | -19.7 | -45.2 | 15.0 | 5.1 | 45.7 |
ROA on year-end assets (%) | -14.2 | -35.1 | 7.9 | 3.0 | 26.1 |
Current ratio (x) | 3.89 | 2.37 | 2.72 | 2.83 | 4.96 |
Debt to equity (x) | 0.04 | 0.04 | 0.12 | 0.12 | 0.08 |
Asset turnover (x) | 0.26 | 0.41 | 0.65 | 0.49 | 0.31 |
R&D as % of revenue | 84.0 | 90.7 | 36.0 | 33.7 | 27.0 |
Derived revenue by source (USD Mn)
| Derived revenue by source (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Ex-China partner revenue (Takeda-related) | 177.8 | 141.0 |
China and Greater China and other | 452.4 | 407.5 |
Ex-China share of total (%) | 28.2 | 25.7 |
In-market sales (USD Mn)
| In-market sales (USD Mn) | FY2024 | FY2025 |
|---|---|---|
FRUZAQLA (ex-China, all markets) | 290.6 | 366.2 |
China products (ELUNATE, SULANDA, ORPATHYS, TAZVERIK) | 210.4 | 158.5 |
Valuation Snapshot
| Multiple | Value |
|---|---|
P/E (trailing) | 142.6 |
P/E (forward) | 39.9 |
EV/Sales | 2.33 |
EV/EBITDA | Not meaningful (negative EBITDA) |
P/B | 2.00 |
P/S | 4.65 |
Valuation Multiples
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
P/S at year-end (x) | 17.26 | 6.30 | 3.67 | 3.99 | 4.39 |
Analyst Conclusions
Management guidance. FY2026 Oncology/Immunology consolidated revenue of $330–450 million (reiterated 30 July 2026). H1 2026 delivered $162.3 million. The GSK upfront ($110 million, payable on closing) would push the year toward the upper half of the range if recognized in 2026; that is our inference, not company guidance. The S&P consensus 3-year revenue growth forecast is 12.55% a year.
Bull case
-
Platform re-rating. The GSK deal values one preclinical-to-Phase I ATTC at up to $1.295 billion. Two more ATTCs are in the clinic, and the company says further partnerships are under discussion.
-
Savolitinib goes global. A positive SAFFRON readout on PFS and OS, the US NDA and a SANOVO 1L filing could turn ORPATHYS from a small China product into a global MET franchise, generating milestones and royalties.
-
China recovery plus a launch wave. Product sales rose 32% in H1 2026, and ATLED, sovleplenib and new fruquintinib indications should support multi-year growth, all backed by $1.37 billion in cash.
Bear case
-
Weak core operating economics. The group posted an operating loss in FY2025 and H1 2026. Reported profits rely on interest income and one-offs, and rising ATTC spend may push the company back into losses.
-
China pricing and competition. The 45% drop in SULANDA sales in FY2025 shows how quickly NRDL entrants can erode revenue. MET and FGFR markets are crowded.
-
Execution and governance. The CEO's leave has lasted more than a year without resolution. ATTC safety in humans is unproven. The TAZVERIK withdrawal shows how a single safety event can remove a product.
Catalysts and monitorables (next 12 months)
-
SAFFRON Presidential Symposium at ESMO 2026, and FDA acceptance of the NDA with a PDUFA date.
-
Closing of the GSK transaction and receipt of the $110 million upfront.
-
NMPA decisions on sovleplenib for ITP and wAIHA.
-
SANOVO full data and a China 1L sNDA.
-
First clinical data from the ATTCs (A251, A580).
-
Any additional multinational ATTC deal.
-
Resolution of the CEO position.
-
FY2026 results (around March 2027) against the $330–450 million guidance.
-
FRUZAQLA US trajectory.
Analyst verdict.
HUTCHMED enters late 2026 transformed from the cash-burning, globally overextended Chi-Med of 2021–2022. It is now a leaner, profitable and heavily capitalized company with a credible second scientific act.
The evidence of the past 90 days is notable: two positive Phase III lung cancer readouts, a fourth in-house China approval, a US NDA, and a $1.3 billion GSK deal for a molecule that had only just entered the clinic. Together they substantially de-risk the narrative that HUTCHMED could not repeat its fruquintinib success.
At about $2.55 billion market capitalization against about $1.28 billion of net cash, the market assigns roughly $1.3 billion of enterprise value. That figure must cover a royalty stream on a fast-growing global CRC drug, a recovering China franchise, the savolitinib global opportunity and an ATTC platform that a major pharmaceutical company has just priced. On a sum-of-the-parts view this looks undemanding. The consensus target of $22 is consistent with that view.
The discount is not irrational, however. Core operations remain loss-making before interest income. China pricing risk has already destroyed half of SULANDA's revenue in a single year. The Acting CEO is also the CFO while the scientific founder-CEO is on extended medical leave. ATTC economics will ultimately depend on human safety and efficacy data that do not yet exist.
Our synthesis is that HUTCHMED offers asymmetric optionality underpinned by its balance sheet. Downside is cushioned by cash representing about half the market value. Upside depends on discrete binary events: the FDA path for savolitinib, sovleplenib approvals, early ATTC data and additional licensing.
Investors should track three things:
-
whether recurring Oncology/Immunology revenue can sustainably exceed $400 million a year;
-
whether R&D can scale without eroding self-sufficiency;
-
whether the board resolves leadership succession within the next two reporting cycles.
Sources consulted (primary documents and aggregators)
-
HUTCHMED, "HUTCHMED Reports 2025 Full Year Results and Business Updates," 5 March 2026 (GlobeNewswire/HKEX/SEC 6-K; Form 20-F filed same day)
-
HUTCHMED, "HUTCHMED Reports 2026 Interim Results," 30 July 2026 (GlobeNewswire; HKEXnews PDF 2026073001567)
-
HUTCHMED, "Announces Appointment of Acting Chief Executive Officer," 25 August 2025
-
HUTCHMED, "Announces US$608 million Divestment of Non-Core Joint Venture," 2 January 2025
-
HUTCHMED, "Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy," 3 September 2026
-
HUTCHMED, "Announces SANOVO Trial...," 31 August 2026
-
HUTCHMED, "Announces Submission of US NDA for ORPATHYS plus TAGRISSO...," 28 September 2026
-
HKEX board composition announcement, 13 May 2026 (via Bulletin Express summary)
-
StockAnalysis.com (S&P Global Market Intelligence / Fiscal.ai) financials, balance sheet, cash flow and statistics, accessed October 2026
-
Equibles (SEC XBRL extraction), CUSIP and FY2025 line items
-
Trade press: PharmaTimes (August 2025), Pharmaceutical Technology, CHEManager, American Pharmaceutical Review (January 2025), Proactive Investors (September 2026)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure / background | Compensation |
|---|---|---|---|
Johnny Cheng (Cheng Chig Fung) | Acting CEO (since 25 August 2025), CFO and Executive Director | CFO since 2008; Executive Director since 2011; aged 58 as of August 2025 | Service agreement: $490,513 a year salary plus discretionary bonus. |
Dr Weiguo Su | CEO (on health-related leave since August 2025), Chief Scientific Officer, Executive Director | Has led HUTCHMED science for about 20 years; architect of the fruquintinib, surufatinib, savolitinib and ATTC platforms | — |
Lorenso Chiu | Deputy CFO | Presented H1 2026 financials | — |
George Yuan | Head of Commercial | H1 2026 webcast | — |
Dr Dai | Head of Discovery and Global Portfolio Management | H1 2026 webcast | — |
David Ng | Head of Investor Relations and Capital Strategies | FY2025 and H1 2026 webcasts | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Category | Committee roles |
|---|---|---|
Dr Dan Eldar | Chairman, Non-executive | Technical Committee member |
Dr Weiguo Su | Executive (CEO, on leave; CSO) | Technical Committee member |
Johnny Cheng | Executive (Acting CEO and CFO) | Sustainability Committee member |
Edith Shih | Non-executive; Company Secretary | Chair of Sustainability Committee |
Ling Yang | Non-executive | — |
Dr Renu Bhatia | Independent Non-executive; Senior and Lead INED | Chair of Nomination; member of Audit and Technical |
Dr Chaohong Hu | Independent Non-executive | Chair of Technical; member of Audit and Nomination |
Prof Tan Shao Weng, Daniel | Independent Non-executive | Member of Sustainability and Technical |
Wong Tak Wai | Independent Non-executive | Chair of Audit |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Area | HUTCHMED asset | Key competitors |
|---|---|---|
3L+ mCRC | Fruquintinib | Bayer (regorafenib/Stivarga); Taiho (trifluridine/tipiracil/Lonsurf, incl. with bevacizumab) |
NETs | Surufatinib | Novartis (everolimus; somatostatin analogs; Lutathera); Pfizer (sunitinib); Ipsen (lanreotide); new NRDL entrants in China (cited by the company) |
MET-driven NSCLC | Savolitinib | Merck KGaA (tepotinib); Novartis (capmatinib); Chinese MET inhibitors (glumetinib, vebreltinib); J&J (amivantamab, post-osimertinib setting) |
FGFR2 ICC | Fanregratinib | Incyte/Innovent (pemigatinib); Taiho (futibatinib) |
ITP / wAIHA | Sovleplenib | Rigel (fostamatinib, Syk); TPO-receptor agonists; Sanofi (rilzabrutinib, BTK) |
DLBCL | HMPL-760 | BTK and CD20/CD3 bispecific developers |
ADC/ATTC modality | ATTC platform | Daiichi Sankyo/AstraZeneca (DXd ADCs); Kelun-Biotech; Hengrui; BeOne (formerly BeiGene); Duality Bio; plus pan-RAS and KRAS developers such as Revolution Medicines |
Peer Comparison FY2024
| Metric | HUTCHMED | BeOne Medicines (BeiGene) | Zai Lab |
|---|---|---|---|
FY2024 revenue (USD Mn) | 630.2 | about 3,810 | about 399 |
FY2024 revenue growth (%) | -24.8 | about 55 | about 50 |
FY2024 GAAP operating margin (%) | -6.9 | about -15 | about -71 |
FY2024 R&D (USD Mn) | 212.1 | about 1,953 | about 234 |
R&D as % of revenue | 33.7 | about 51 | about 59 |
Recent Developments
--
